Drug Profile
Research programme: inhaled dry powder respiratory therapeutics - TFF Phartmaceuticals
Alternative Names: TFF Triple ComboLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator TFF Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Respiratory tract disorders
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in USA (Inhalation, Powder)
- 28 May 2022 No recent reports of development identified for research development in Respiratory-tract-disorders in USA (Inhalation, Powder)
- 03 Sep 2019 Early research in Chronic obstructive pulmonary disease in USA (Inhalation)